There are currently over 20 different compounds in the process of development for treating back-of-the-eye diseases, but Macugen™ looks to be victorious as the first major competitor for Novartis’ and QLT’s Visudyne®, which has had free reign in the wet age related macular degeneration (AMD) market since it was launched in 2000.